Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma
Cutaneous Melanoma|Mucosal Melanoma
DRUG: Nemvaleukin Alfa Subcutaneous|DRUG: Nemvaleukin Alfa Intravenous|DRUG: Nemvaleukin Alfa Intravenous Less Frequent Dosing|DRUG: Pembrolizumab
Centrally-assessed overall response rate (ORR) (Cohort 1 and 2), * ORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug
* Response will be based on RECIST v1.1 criteria, Assessed up to 2 years from the first dose|Investigator-assessed overall response rate (ORR) (Cohort 3 and 4), ORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug, Assessed up to 2 years from the first dose
Centrally-assessed duration of response (DOR) (Cohort 1 and 2), -DOR is defined as the time from the first documentation of complete or partial response to the first documentation of either objective tumor progression or death, Assessed up to 2 years from the first dose|Investigator-assessed duration of response (DOR) (Cohort 3 and 4), -DOR is defined as the time from the first documentation of complete or partial response to the first documentation of either objective tumor progression or death, Assessed up to 2 years from the first dose|Centrally-assessed progression free survival (PFS) (Cohort 1 and 2), -PFS is defined as the time from each respective patient's first dose of nemvaleukin to either the first documentation of objective tumor progression or death, Assessed up to 2 years from the first dose|Investigator-assessed progression free survival (PFS) (Cohort 3 and 4), -PFS is defined as the time from each respective patient's first dose of nemvaleukin to either the first documentation of objective tumor progression or death, Assessed up to 2 years from the first dose|Centrally-assessed disease control rate (DCR) (Cohort 1 and 2), -DCR is defined as the proportion of patients with objective evidence of complete response, partial response, or stable disease on 2 consecutive protocol-required disease assessments, Assessed up to 2 years from the first dose|Investigator-assessed disease control rate (DCR) (Cohort 3 and 4), -DCR is defined as the proportion of patients with objective evidence of complete response, partial response, or stable disease on 2 consecutive protocol-required disease assessments, Assessed up to 2 years from the first dose|Centrally-assessed time to response (TTR) (Cohort 1 and 2), -TTR is defined as the time from patient's first dose of nemvaleukin to the first documentation of complete response or partial response, Assessed up to 2 years from the first dose|Investigator-assessed time to response (TTR) (Cohort 3 and 4), -TTR is defined as the time from patient's first dose of nemvaleukin to the first documentation of complete response or partial response, Assessed up to 2 years from the first dose|Incidence of treatment-emergent adverse events (All cohorts), Assessed up to 2 years from the first dose|Investigator-assessed overall response rate (ORR) (Cohort 1 and 2), ORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug, Assessed up to 2 years from the first dose|Investigator-assessed immune overall response rate (iORR) (All cohorts), -iORR is defined as the number of patients exhibiting a complete response (CR) or partial response (PR) divided by the number of patients who received the study drug., Assessed up to 2 years from the first dose|Investigator-assessed immune duration of response (iDOR) (All cohorts), -iDOR is defined as the time from the first documentation of complete or partial response to the first documentation of either objective tumor progression or death, Assessed up to 2 years from the first dose|Investigator-assessed immune progression free survival (iPFS) (All cohorts), -iPFS is defined as the time from each respective patient's first dose of nemvaleukin to either the first documentation of objective tumor progression or death, Assessed up to 2 years from the first dose|Investigator-assessed immune disease control rate (iDCR) (All cohorts), -iDCR is defined as the proportion of patients with objective evidence of complete response, partial response, or stable disease on 2 consecutive protocol-required disease assessments, Assessed up to 2 years from the first dose|Investigator-assessed immune time to response (iTTR) (All cohorts), -iTTR is defined as the time from patient's first dose of nemvaleukin to the first documentation of complete or partial response, Assessed up to 2 years from the first dose
This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma